Small-caps have done better than their bigger brethren so far in 2019, and these three stocks are a reason why.
Horizon Pharma's stock price skyrockets after the Dublin-based biotech reports positive results for a new drug to treat a rare but devastating eye disease.
And why I won't recommend any other stocks in these markets, right now.
Shares of Sarepta Therapeutics surge after the company announces an early stage study of a gene-therapy treatment that could benefit patients with a rare form of muscular dystrophy shows promising results.
Quick takes on fourth-quarter results from these 3 biotech names.
Here's how to trade XLRN stock right now.
France's Ipsen agrees to buy Clementia Pharmaceuticals in a deal worth up to $1.31 billion.
Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.
Predicted price would be nearly $3 billion over Spark's market cap as of Friday's close, but Roche spokesman claims report is 'market rumor.'
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.